Plasma fractionation issues

Albert Farrugia, Theo Evers, Pierre Francois Falcou, Thierry Burnouf, Luiz Amorim, Sylvia Thomas

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)


Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.

Original languageEnglish
Pages (from-to)88-93
Number of pages6
Issue number2
Publication statusPublished - Apr 2009
Externally publishedYes


  • Factor VIII
  • IVIG
  • Procurement of plasma
  • Protein fractionation
  • Viral inactivation

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • General Immunology and Microbiology
  • Bioengineering
  • Biotechnology
  • Pharmacology


Dive into the research topics of 'Plasma fractionation issues'. Together they form a unique fingerprint.

Cite this